| Pinto, Antonio |
| Completed | 3 | 500 | Europe | Doxorubicin, Bleomycin, Vinblastine, Dacarbazine | Fondazione Italiana Linfomi - ETS | Hodgkin Lymphoma | 11/21 | 11/24 | | |
FIL-RougeBIO, NCT05066555: Circulating Tumor DNA Genotyping for Biological Monitoring of Patients Treated in the FIL-Rouge Clinical Trial |
|
|
| Completed | 3 | 100 | Europe | | Fondazione Italiana Linfomi - ETS | Hodgkin Lymphoma | 11/21 | 11/24 | | |
NCT04442022 / 2020-000605-84: A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) with or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma |
|
|
| Recruiting | 2/3 | 501 | Europe, US, RoW | Selinexor (combination therapy), Placebo matching for Selinexor (combination therapy), Rituximab (combination therapy), Gemcitabine (combination therapy), Dexamethasone (combination therapy), Cisplatin (combination therapy), Selinexor (continuous therapy), Placebo matching for Selinexor (continuous therapy) | Karyopharm Therapeutics Inc | Relapsed/refractory Diffuse Large B-cell Lymphoma | 12/24 | 12/25 | | |
| Terminated | 2 | 22 | Europe | ERDAFITINIB, JNJ -42756493, WHO NUMBER 10147 | Lung Cancer Group Cologne | Lung Cancer, NSCLC, Pulmonary Neoplasm, Squamous Cell Lung Cancer, NSCLC Stage IV | 09/22 | 10/22 | | |
NCT03731234: Ibrutinib + R-CHOP Followed by Ibrutinib Maintenance |
|
|
| Active, not recruiting | 2 | 75 | Europe | Ibrutinib, IMBRUVICA (commercial name) | Fondazione Italiana Linfomi - ETS, Janssen-Cilag S.p.A. | DLBCL | 07/24 | 07/27 | | |
FIL_COLUMN, NCT05249959: Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients. |
|
|
| Recruiting | 2 | 49 | Europe | Consolidation with ADCT-402 (loncastuximab tesirine) after salvage immunochemotherapy at standard dose (R-BAC, Rituximab - Bendamustine, Ara-C)), Consolidation with ADCT-402 (loncastuximab tesirine) after salvage immunochemotherapy at reduced dose (R-BAC, Rituximab - Bendamustine, Ara-C) | Fondazione Italiana Linfomi - ETS | Relapsed Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma | 04/26 | 04/29 | | |
| Recruiting | 2 | 244 | Europe, Canada, US, RoW | Selinexor, KPT-330 | Karyopharm Therapeutics Inc | Diffuse Large B-cell Lymphoma | 04/27 | 11/27 | | |
|
|
|
|
|
|
|
|
|
FIL_Tisle-HL, NCT05977673: Efficacy and Safety of Frontline Tislelizumab in Patients With de Novo Hodgkin Lymphoma Unsuitable for Standard Frontline Chemotherapy |
|
|
| Recruiting | 2 | 28 | Europe | Tislelizumab | Fondazione Italiana Linfomi - ETS | Hodgkin Lymphoma | 11/27 | 11/29 | | |
| Recruiting | 1/2 | 60 | Europe, US | EO2463, lenalidomide, Revlimid, rituximab, MabThera | Enterome | Follicular Lymphoma, Marginal Zone Lymphoma | 05/26 | 05/32 | | |
NCT02576496: Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies |
|
|
| Completed | 1 | 106 | Europe, US | Tinostamustine, EDO-S101 | Mundipharma Research Limited | Hematological Malignancies, Multiple Myeloma, Hodgkin's Lymphoma, Cutaneous T Cell Lymphoma | 05/23 | 11/23 | | |
NCT04352556: COVID19-hematological Malignancies: the Italian Hematology Alliance |
|
|
| Recruiting | N/A | 250 | Europe | | Ospedale di Circolo - Fondazione Macchi | SARS-CoV-2 Infection, Hematological Malignancies | 10/22 | 10/22 | | |
NCT06299553: Study to Evaluate the Effectiveness of Tafasitamab in Combination With Lenalidomide Followed by Tafasitamab Monotherapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma Non-transplant Eligible Patients in Italy (PRO-MIND) |
|
|
| Recruiting | N/A | 200 | Europe | | Incyte Biosciences Italy S.r.l, Advice Pharma Group srl | DLBCL - Diffuse Large B Cell Lymphoma | 06/25 | 06/27 | | |
NCT06600568: Novel Therapeutic Approach for Human T-cell Malignancies |
|
|
| Recruiting | N/A | 120 | Europe | Translation analysis | Istituto Oncologico Veneto IRCCS, Istituto Nazionale Tumori IRCSS-Fondazione G.Pascale | T-Cell Leukemia/Lymphoma, Adult | 07/26 | 07/26 | | |
